Incomplete Antibodies May Reduce ABO Cross-Match Incompatibility: A Pilot Study
Objective: Any erythrocyte transfusion among humans having type A or B blood groups is impossible due to antibodies causing fatal transfusion complications. A cross-match test is performed to prevent immune transfusion complications before transfusion. Our hypothesis is that the fragment antibody (F...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Publishing House
2018-02-01
|
| Series: | Turkish Journal of Hematology |
| Subjects: | |
| Online Access: | https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-08931 |
| _version_ | 1797909164550258688 |
|---|---|
| author | Mehmet Özen Soner Yılmaz Tülin Özkan Yeşim Özer Aliye Aysel Pekel Asuman Sunguroğlu Günhan Gürman Önder Arslan |
| author_facet | Mehmet Özen Soner Yılmaz Tülin Özkan Yeşim Özer Aliye Aysel Pekel Asuman Sunguroğlu Günhan Gürman Önder Arslan |
| author_sort | Mehmet Özen |
| collection | DOAJ |
| description | Objective: Any erythrocyte transfusion among humans having type A or B blood groups is impossible due to antibodies causing fatal transfusion complications. A cross-match test is performed to prevent immune transfusion complications before transfusion. Our hypothesis is that the fragment antibody (Fab) part of the antibody (incomplete antibody) may be used to prevent an immune stimulus related to the complete antibody. Therefore, we designed a pilot study to evaluate the effectiveness of these incomplete antibodies using cross-match tests. Materials and Methods: Pepsin enzyme and staphylococcal protein A columns were used to cut anti-A and anti-B monoclonal antibodies and purify their Fab (2) fragments, respectively. An Rh-positive erythrocyte suspension with purified anti-A Fab (2) solution and B Rh-positive erythrocyte suspension with purified anti-B Fab (2) solution were combined correspondingly. Cross-match tests were performed by tube and gel centrifugation methods. The agglutination levels due to the anti-A and anti-B Fab (2) antibodies and their effects on the agglutination normally observed with complete antibodies were then measured. Results: No agglutination for the purified incomplete anti-A Fab (2) with A Rh+ erythrocyte and anti-B Fab (2) with B Rh+ erythrocyte combinations was observed in the tube cross-match tests. These agglutination levels were 1+ in two wells in the gel centrifugation cross-match tests. Fab (2)-treated erythrocytes were also resistant to the agglutination that normally occurs with complete antibodies. Conclusion: We determined that the Fab (2) fragments of antibodies may not only be used to obtain a mild or negative reaction when compared to complete antibodies, but they might also be used for decreasing ABO incompatibility. Incomplete antibodies might be a therapeutic option in autoimmune hemolytic anemia and they may also be used in solid organ or hematopoietic stem cell transplantation. Therefore, we have planned an in vivo study to prove these in vitro findings. |
| first_indexed | 2024-04-10T11:04:07Z |
| format | Article |
| id | doaj.art-1ea27d5ff99c46c4a4fbb62a27d5014e |
| institution | Directory Open Access Journal |
| issn | 1308-5263 |
| language | English |
| last_indexed | 2024-04-10T11:04:07Z |
| publishDate | 2018-02-01 |
| publisher | Galenos Publishing House |
| record_format | Article |
| series | Turkish Journal of Hematology |
| spelling | doaj.art-1ea27d5ff99c46c4a4fbb62a27d5014e2023-02-15T16:19:31ZengGalenos Publishing HouseTurkish Journal of Hematology1308-52632018-02-01351546010.4274/tjh.2016.0504TJH-08931Incomplete Antibodies May Reduce ABO Cross-Match Incompatibility: A Pilot StudyMehmet Özen0Soner Yılmaz1Tülin Özkan2Yeşim Özer3Aliye Aysel Pekel4Asuman Sunguroğlu5Günhan Gürman6Önder Arslan7Ufuk University Faculty of Medicine, Department of Hematology, Ankara, TurkeyUniversity of Health Sciences, Gülhane Training and Research Hospital, Blood Bank Unit, Ankara, TurkeyAnkara University Faculty of Medicine, Department of Medical Biology, Ankara, TurkeyAnkara University Faculty of Medicine, Unit of Blood Bank, Ankara, TurkeyUniversity of Health Sciences, Gülhane Training and Research Hospital, Clinic of Immunology and Allergy Diseases, Ankara, TurkeyAnkara University Faculty of Medicine, Department of Medical Biology, Ankara, TurkeyAnkara University Faculty of Medicine, Department of Hematology, Ankara, TurkeyAnkara University Faculty of Medicine, Department of Hematology, Ankara, TurkeyObjective: Any erythrocyte transfusion among humans having type A or B blood groups is impossible due to antibodies causing fatal transfusion complications. A cross-match test is performed to prevent immune transfusion complications before transfusion. Our hypothesis is that the fragment antibody (Fab) part of the antibody (incomplete antibody) may be used to prevent an immune stimulus related to the complete antibody. Therefore, we designed a pilot study to evaluate the effectiveness of these incomplete antibodies using cross-match tests. Materials and Methods: Pepsin enzyme and staphylococcal protein A columns were used to cut anti-A and anti-B monoclonal antibodies and purify their Fab (2) fragments, respectively. An Rh-positive erythrocyte suspension with purified anti-A Fab (2) solution and B Rh-positive erythrocyte suspension with purified anti-B Fab (2) solution were combined correspondingly. Cross-match tests were performed by tube and gel centrifugation methods. The agglutination levels due to the anti-A and anti-B Fab (2) antibodies and their effects on the agglutination normally observed with complete antibodies were then measured. Results: No agglutination for the purified incomplete anti-A Fab (2) with A Rh+ erythrocyte and anti-B Fab (2) with B Rh+ erythrocyte combinations was observed in the tube cross-match tests. These agglutination levels were 1+ in two wells in the gel centrifugation cross-match tests. Fab (2)-treated erythrocytes were also resistant to the agglutination that normally occurs with complete antibodies. Conclusion: We determined that the Fab (2) fragments of antibodies may not only be used to obtain a mild or negative reaction when compared to complete antibodies, but they might also be used for decreasing ABO incompatibility. Incomplete antibodies might be a therapeutic option in autoimmune hemolytic anemia and they may also be used in solid organ or hematopoietic stem cell transplantation. Therefore, we have planned an in vivo study to prove these in vitro findings.https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-08931transfusion medicinered blood cellscomplicationshumoral immune response |
| spellingShingle | Mehmet Özen Soner Yılmaz Tülin Özkan Yeşim Özer Aliye Aysel Pekel Asuman Sunguroğlu Günhan Gürman Önder Arslan Incomplete Antibodies May Reduce ABO Cross-Match Incompatibility: A Pilot Study Turkish Journal of Hematology transfusion medicine red blood cells complications humoral immune response |
| title | Incomplete Antibodies May Reduce ABO Cross-Match Incompatibility: A Pilot Study |
| title_full | Incomplete Antibodies May Reduce ABO Cross-Match Incompatibility: A Pilot Study |
| title_fullStr | Incomplete Antibodies May Reduce ABO Cross-Match Incompatibility: A Pilot Study |
| title_full_unstemmed | Incomplete Antibodies May Reduce ABO Cross-Match Incompatibility: A Pilot Study |
| title_short | Incomplete Antibodies May Reduce ABO Cross-Match Incompatibility: A Pilot Study |
| title_sort | incomplete antibodies may reduce abo cross match incompatibility a pilot study |
| topic | transfusion medicine red blood cells complications humoral immune response |
| url | https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-08931 |
| work_keys_str_mv | AT mehmetozen incompleteantibodiesmayreduceabocrossmatchincompatibilityapilotstudy AT soneryılmaz incompleteantibodiesmayreduceabocrossmatchincompatibilityapilotstudy AT tulinozkan incompleteantibodiesmayreduceabocrossmatchincompatibilityapilotstudy AT yesimozer incompleteantibodiesmayreduceabocrossmatchincompatibilityapilotstudy AT aliyeayselpekel incompleteantibodiesmayreduceabocrossmatchincompatibilityapilotstudy AT asumansunguroglu incompleteantibodiesmayreduceabocrossmatchincompatibilityapilotstudy AT gunhangurman incompleteantibodiesmayreduceabocrossmatchincompatibilityapilotstudy AT onderarslan incompleteantibodiesmayreduceabocrossmatchincompatibilityapilotstudy |